Esperion Therapeutics ESPR Proceeds from issuance of common stock, net of issuance costs
Proceeds from issuance of common stock, net of issuance costs at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept espr:ProceedsFromIssuanceOfCommonStockAndWarrants.
The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's proceeds from issuance of common stock, net of issuance costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's proceeds from issuance of common stock, net of issuance costs?
- Esperion Therapeutics (ESPR) reported proceeds from issuance of common stock, net of issuance costs of $18.15M in Q4 2025.
- How has Esperion Therapeutics's proceeds from issuance of common stock, net of issuance costs changed year-over-year?
- Esperion Therapeutics's proceeds from issuance of common stock, net of issuance costs decreased by 19.9% year-over-year, from $22.67M to $18.15M.
- What is the long-term trend for Esperion Therapeutics's proceeds from issuance of common stock, net of issuance costs?
- Over 4 years (2021 to 2025), Esperion Therapeutics's proceeds from issuance of common stock, net of issuance costs has grown at a -23.2% compound annual growth rate (CAGR), from $208.98M to $72.6M.
- What does proceeds from issuance of common stock, net of issuance costs mean?
- This represents the total net cash inflow from the issuance of common stock and the exercise of warrants, after accounting for issuance costs. It reflects the capital raised through equity markets to fund operations, research, or debt repayment. This metric is a primary indicator of the company's reliance on equity financing and its impact on shareholder dilution.